Abstract: An aluminoborate glass composition, including B2O3, Al2O3, P2O5, Na2O, and CaO, as defined herein. Also disclosed are bioactive compositions including the disclosed aluminoborate glass composition, a suitable fluid, and at least one live cell. Also disclosed is method of limiting the amount of boron released into an aqueous solution from a disclosed aluminoborate-containing glass composition as defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein.

Abstract: Cross-linked shear-thinning fluids of pectic acid demonstrating increased viscosity with decreasing shear, as well as methods of producing and using the same. A shear-thinning fluid includes an aqueous solution of pectic acid cross-linked by a divalent cation is disclosed. The pectic acid may be present in an amount ranging from about 0.5 to about 3.0% (w/v), the divalent cation may be present at a concentration of from about 0.5 mM to about 7.0 mM, and the viscosity of the shear-thinning fluid increases with decreasing shear. These cross-linked shear-thinning fluids of pectic acid can be utilized for controlled release formulations, cell encapsulation, and 3D printing, and provide for an improved balance between structure fidelity/mechanical stability and cell viability.

Abstract: A dental formulation including: a bioactive glass composition as defined herein, in an effective amount; and a suitable carrier as defined herein, in an effective amount. Also disclosed is a method of making and using the dental formulation to treat, for example, dentin sensitivities.

Abstract: A bioactive borate glass composition including, for example: 30 to 60% B2O3; 0.5 to 20% ZrO2; 3 to 30% Na2O; 0.1 to 15% K2O; 0.1 to 15% MgO; 5 to 30% CaO; and 1 to 5% P2O5 in mole percents based on 100 mol % of the total composition. Also disclosed is a method of making and method of using the compositions and the bioactive borate glass dentin treatment formulations.

Abstract: A bioactive glass composition including: 50 to 70% SiO2; 0.1 to 10% Al2O3, 5 to 30% Na2O, 0.1 to 15% K2O, 0.1 to 15% MgO, 0.1 to 20% CaO, and 5 to 10% P2O5, based on a 100 wt % of the composition. Also disclosed is a method of making the bioactive glass composition.

Abstract: A chemically strengthened bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions.

Abstract: A bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions.

Abstract: A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

Abstract: A bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions.

Abstract: An aluminoborate glass composition, including B2O3, Al2O3, P2O5, Na2O, and CaO, as defined herein. Also disclosed are bioactive compositions including the disclosed aluminoborate glass composition, a suitable fluid, and at least one live cell. Also disclosed is method of limiting the amount of boron released into an aqueous solution from a disclosed aluminoborate-containing glass composition as defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein.

Abstract: An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds.

Abstract: A pharmaceutical composition including at least one compound of the Formulas (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as defined herein. Also disclosed is a method of treatment of diseases which are pathophysiologically related to GPR35, the GPR35-hERG signaling complex, or both, as defined herein.

Abstract: Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R1, R2, R3, R6, R5, and R4 are defined herein. These compounds can be useful as therapeutic agents for modulating hERG ion channels, and for improving prevention and treatment of hERG associated cardiac repolarization disorders.

Abstract: Disclosed are compositions and methods related to identification of modulators of EGFR and VEGFR.

Abstract: Disclosed are methods to characterize PI3K inhibitors and Rho kinase inhibitors using label-free cellular assays. Disclosed are also methods to characterize a cell whether it has a deregulated PI3K pathway or not.

Abstract: Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject.

Abstract: A cell culture article includes a porous substrate having a plurality of pores and a plurality of interstices in communication with the pores. At least some of the plurality of pores and interstices are sufficiently large for two or more mammary epithelial cells to cluster within the pores or interstices. Non-malignant mammary epithelial cells or breast cancer cells may not attach strongly to the substrate surface, which may encourage cell-cell interaction. In many cases, the article is desirably free of components of unknown origin. The articles may be capable of maintaining culture of malignant and non-malignant mammary epithelial cells and allowing for development of in vivo-like morphologies or characteristics of such cells.